Cash/Burn From SEC Filing For Period: 

Q1 '20

APTO

Aptose Biosciences

Cash

$90M

Burn Rate

-$11.5M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

CG-806 (BTK Inhibitor)

B-cell malignancies (NHL & CLL)

Phase 1 (Data Presentation at ASH)

December 5, 2020

APTO-253

RR Acute Myelogenous Leukemia/ HR Myelodysplasia

Phase 1 (ASH Data Presentation)

Dec 5-8, 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

APTO EHA 2020 ...

APTO is presenting data at EHA 2020 for their BTK and FLT-3 inhibitor CG-806 at EHA. Get our take on the likely movement and our investment strategy going forward. CLICK HERE (Free sign-up required fo...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon